Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed metastatic melanoma~  * Stage IV disease~ * Progressive disease~ * No known standard therapy that is potentially curative or proven capable of extending life expectancy exists~* Planning to undergo chemotherapy with paclitaxel and carboplatin OR temozolomide alone for progressive disease~* Measurable disease as defined by RECIST criteria~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* ANC ≥ 1,500/mL~* Platelet count ≥ 100,000/mL~* Hemoglobin ≥ 9 g/dL~* Creatinine ≤ 2.5 x upper limit of normal (ULN)~* AST ≤ 3 x ULN~* Alkaline phosphatase ≤ 3.0 x ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 month after completion of study therapy~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Active infection~ * NYHA class III or IV congestive heart failure~* No history of other malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix~* Willing to provide research blood samples~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* At least 4 weeks since prior radiotherapy~* At least 4 weeks since prior chemotherapy (patients who received chemotherapy in the metastatic setting)~  * No prior chemotherapy treatment with agents similar to study drugs~* No prior chemotherapy in the metastatic setting (for chemo-naive patients)~* No concurrent enrollment in a different clinical study in which investigational procedures or agents are being used~* No other concurrent investigational agents~* No other concurrent chemotherapy or radiotherapy, including palliative radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- PC (previously treated) (Type: EXPERIMENTAL): Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
- PC (chemo naive) (Type: EXPERIMENTAL): Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
- TMZ (previously treated) (Type: EXPERIMENTAL): Previously chemotherapy treated cohorts: Temozolomide (TMZ)
- TMZ (chemo naive) (Type: EXPERIMENTAL): Chemotherapy-naive cohorts: Temozolomide (TMZ)

Based on this trial design, predict the completion outcome and termination type (if applicable).